Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response

Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in c...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Josefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, Jun Guo, Hanine Rafidi, Danielle Mandikian, Yonglian Sun, Zhonghua Lin, Kellen Schneider, Pamela Zhang, Rajesh Vij, Danielle Sharpnack, Pamela Chan, Cecile de la Cruz, Jack Sadowsky, Dhaya Seshasayee, James T. Koerber, Thomas H. Pillow, Gail D. Phillips, Rebecca K Rowntree, C. Andrew Boswell, Katherine R. Kozak, Andrew G. Polson, Paul Polakis, Shang-Fan Yu, Peter S. Dragovich, Nicholas J. Agard
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis Group 2021-01-01
Collection:mAbs
Sujets:
Antibody-drug conjugate
Ly6E
virus-like particles
ADC resistance
antibody discovery
Accès en ligne:https://www.tandfonline.com/doi/10.1080/19420862.2020.1862452
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires